...
首页> 外文期刊>Cardiovascular & hematological agents in medicinal chemistry >Treating depression in coronary artery disease and chronic heart failure: What's new in using selective serotonin re-uptake inhibitors?
【24h】

Treating depression in coronary artery disease and chronic heart failure: What's new in using selective serotonin re-uptake inhibitors?

机译:治疗冠状动脉疾病和慢性心力衰竭的抑郁症:使用选择性5-羟色胺再摄取抑制剂的最新进展是什么?

获取原文
获取原文并翻译 | 示例
           

摘要

Depression is a common co-morbidity in patients with cardiovascular diseases such as chronic coronary artery disease, acute coronary syndromes, post by-pass surgery and chronic heart failure. The presence of depression is independently associated with a decline in health status and an increase in the risk of hospitalization and death for patients with coronary artery disease or congestive heart failure. Novel treatment modalities such as selective serotonin re-uptake inhibitors (SSRIs) may improve depressive symptoms and prognosis of post-myocardial infarction and heart failure patients interacting with the common pathophysiological mechanisms of depression and cardiovascular disease. This review summarizes current experimental and clinical evidence regarding the effects of SSRIs on platelet functions, immune and neurohormonal activation, and cardiac rhythm disturbances in patients with cardiovascular disease.
机译:抑郁症是患有心血管疾病(例如慢性冠状动脉疾病,急性冠状动脉综合症,旁路手术后和慢性心力衰竭)的患者的常见合并症。抑郁症的存在与冠状动脉疾病或充血性心力衰竭患者的健康状况下降以及住院和死亡风险的增加相关。选择性5-羟色胺再摄取抑制剂(SSRIs)等新型治疗方式可改善抑郁症症状,并改善与心肌梗塞和心血管疾病的常见病理生理机制相互作用的心肌梗塞和心力衰竭患者的预后。这篇综述总结了关于SSRIs对心血管疾病患者血小板功能,免疫和神经激素激活以及心律失常的影响的实验和临床证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号